<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/'><id>tag:blogger.com,1999:blog-2983847494764530248.post4113800476119621748..comments</id><updated>2008-03-25T21:02:36.530+09:00</updated><category term='★★★'/><category term='Need for data'/><category term='*Case2002'/><category term='*Case2009'/><category term='Injunction'/><category term='*Case1991-2000'/><category term='Selection invention'/><category term='Amendment/New matter'/><category term='*Case2010'/><category term='Product-by-process'/><category term='*Case1971-1980'/><category term='Patent term extension'/><category term='Formality'/><category term='*Case2006'/><category term='Priority right'/><category term='・Composition/Formulation'/><category term='　・Purification/Impurity'/><category term='Post-published prior art'/><category term='*Case2011'/><category term='*Topics'/><category term='*Pharma/IP news'/><category term='Inventive step/Obviousness'/><category term='・Package/Container'/><category term='・Dosage regimen'/><category term='*Case2003'/><category term='★'/><category term='・Indication'/><category term='Infringement'/><category term='Utility/Description requirement'/><category term='Inventorship/Remuneration'/><category term='*Case2007'/><category term='*Case2012'/><category term='・Polymorph'/><category term='Design'/><category term='*Case2004'/><category term='*Case2001'/><category term='・・・Thanks for your comments'/><category term='・Screening assay/tool'/><category term='Trademark/Unfair competition'/><category term='・Optical isomer'/><category term='・Process/Manufacture'/><category term='・Salt/Solvate'/><category term='*Case2008'/><category term='・Combination therapy'/><category term='*Case2005'/><category term='・Purification/Impurity'/><category term='Novelty'/><category term='Advantageous effects'/><category term='★★'/><category term='・Compound'/><title type='text'>Comments on 「医薬系 "特許的" 判例」 ブログ: 2008.03.18 「OSI Pharmaceuticals Announces That the...</title><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://www.tokkyoteki.com/feeds/4113800476119621748/comments/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/2983847494764530248/4113800476119621748/comments/default'/><link rel='alternate' type='text/html' href='http://www.tokkyoteki.com/2008/03/20080318-osi-pharmaceuticals-announces.html'/><author><name>Fubuki</name><uri>http://www.blogger.com/profile/17180300759644628572</uri><email>noreply@blogger.com</email><gd:image xmlns:gd='http://schemas.google.com/g/2005' rel='http://schemas.google.com/g/2005#thumbnail' width='27' height='32' src='http://1.bp.blogspot.com/_-QTWVbT1hWM/TUl3ryAu32I/AAAAAAAAAw4/_8NIMsvBny4/s220/Fubuki.JPG'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>2</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-2983847494764530248.post-7169811340676561450</id><published>2008-03-25T21:02:00.000+09:00</published><updated>2008-03-25T21:02:00.000+09:00</updated><title type='text'>コメントありがとうございます。&lt;br&gt;ご指摘のとおり、米国でも下記のような機能クレームで特許（US ...</title><content type='html'>コメントありがとうございます。&lt;BR/&gt;ご指摘のとおり、米国でも下記のような機能クレームで特許（US 6,303,661 B1）となっています。ライセンスをあらかじめ得ておくか、それとも訴訟のリスクを背負うか、DPPIV inhibitorを開発する各企業の判断が問われますね。&lt;BR/&gt;&lt;BR/&gt;US 6,303,661 B1&lt;BR/&gt;Claims:&lt;BR/&gt;1. A method for lowering elevated blood glucose levels in mammals resulting from food intake comprising administering at least one oral administration of a therapeutically effective amount of at least one inhibitor of Dipeptidyl Peptidase (DP IV) or of DP IV-like enzyme activity. &lt;BR/&gt;&lt;BR/&gt;2. The method according to claim 1, wherein said at least one inhibitor is selected from the group consisting of alanyl pyrrolidine, isoleucyl thiazolidine, and N-valyl prolyl, O-benzoyl hydroxylamine. &lt;BR/&gt;&lt;BR/&gt;3. The method according to claim 1, wherein said at least one inhibitor is administered in combination with at least one carrier substance. &lt;BR/&gt;&lt;BR/&gt;4. The method according to claim 1, wherein said at least one inhibitor is administered in multiple administrations. &lt;BR/&gt;&lt;BR/&gt;5. The method according to claim 1, wherein said amount is between 1.0 mg to 10.0 mg per kilogram of the inhibitor compound. &lt;BR/&gt;&lt;BR/&gt;6. The method according to claim 1, wherein the mammals demonstrate clinically inappropriate basal and post-prandial hyperglycemia. &lt;BR/&gt;&lt;BR/&gt;7. The method according to claim 1, wherein the administration is for the prevention or alleviation of pathological abnormalities of metabolism of mammals such as glucosuria, hyperlipidaemia, metabolic acidosis and Diabetes mellitus. &lt;BR/&gt;&lt;BR/&gt;8. A method for lowering elevated blood glucose levels in mammals resulting from food intake comprising the administration of a therapeutically effective amount of an inhibitor of DP-IV enzyme activity comprising isoleucyl thiazolidine. &lt;BR/&gt;&lt;BR/&gt;9. A method for lowering elevated blood glucose levels in mammals resulting from food intake comprising the oral administration of a therapeutically effective amount of an inhibitor of DP-IV enzyme activity selected from the group consisting of alanyl pyrrolidine and isoleucyl thiazolidine.</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/2983847494764530248/4113800476119621748/comments/default/7169811340676561450'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/2983847494764530248/4113800476119621748/comments/default/7169811340676561450'/><link rel='alternate' type='text/html' href='http://www.tokkyoteki.com/2008/03/20080318-osi-pharmaceuticals-announces.html?showComment=1206446520000#c7169811340676561450' title=''/><author><name>Fubuki</name><uri>http://www.blogger.com/profile/17180300759644628572</uri><email>noreply@blogger.com</email><gd:image xmlns:gd='http://schemas.google.com/g/2005' rel='http://schemas.google.com/g/2005#thumbnail' width='27' height='32' src='http://bp3.blogger.com/_-QTWVbT1hWM/RzL-ek9h6mI/AAAAAAAAABQ/ncC1dV9iwjE/s400/yuzuki2.JPG'/></author><thr:in-reply-to xmlns:thr='http://purl.org/syndication/thread/1.0' href='http://www.tokkyoteki.com/2008/03/20080318-osi-pharmaceuticals-announces.html' ref='tag:blogger.com,1999:blog-2983847494764530248.post-4113800476119621748' source='http://www.blogger.com/feeds/2983847494764530248/posts/default/4113800476119621748' type='text/html'/><gd:extendedProperty xmlns:gd='http://schemas.google.com/g/2005' name='blogger.itemClass' value='pid-2129374184'/></entry><entry><id>tag:blogger.com,1999:blog-2983847494764530248.post-7737832386604019347</id><published>2008-03-24T21:02:00.000+09:00</published><updated>2008-03-24T21:02:00.000+09:00</updated><title type='text'>米国特許はどうするんでしょうね。</title><content type='html'>米国特許はどうするんでしょうね。</content><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/2983847494764530248/4113800476119621748/comments/default/7737832386604019347'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/2983847494764530248/4113800476119621748/comments/default/7737832386604019347'/><link rel='alternate' type='text/html' href='http://www.tokkyoteki.com/2008/03/20080318-osi-pharmaceuticals-announces.html?showComment=1206360120000#c7737832386604019347' title=''/><author><name>ぎっちょん</name><email>noreply@blogger.com</email><gd:image xmlns:gd='http://schemas.google.com/g/2005' rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img1.blogblog.com/img/blank.gif'/></author><thr:in-reply-to xmlns:thr='http://purl.org/syndication/thread/1.0' href='http://www.tokkyoteki.com/2008/03/20080318-osi-pharmaceuticals-announces.html' ref='tag:blogger.com,1999:blog-2983847494764530248.post-4113800476119621748' source='http://www.blogger.com/feeds/2983847494764530248/posts/default/4113800476119621748' type='text/html'/><gd:extendedProperty xmlns:gd='http://schemas.google.com/g/2005' name='blogger.itemClass' value='pid-868364092'/></entry></feed>
